Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Jean‐Charles Soria et al.|The Lancet Oncology|2018Cited by 614
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albigès, Fabrice Barlési, Audrey Perret et al.|Nature Cancer|2020Cited by 119
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive studyGuillaume Manson, Jean‐Marie Michot|Journal for ImmunoTherapy of Cancer|2019Cited by 105
How to manage patients with corticosteroids in oncology in the era of immunotherapy?Mihaela Aldea, Jean‐Marie Michot, Émeline Orillard et al.|European Journal of Cancer|2020Cited by 87
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic reviewChiara Corti, Giuseppe Curigliano, Gabriele Antonarelli et al.|Annals of Oncology|2021Cited by 81